CASE WESTERN RESERVE UNIVERSITY

NervGen Pharma announced a $10 million private placement to advance NVG-291, a first-in-class therapeutic peptide targeting nervous system repair for spinal cord injury.

A large medical records study found that receiving six or more gabapentin prescriptions for chronic low back pain was associated with 29% increased dementia risk and 85% increased mild cognitive impairment risk within 10 years.

NervGen Pharma has appointed Dr. Randall Kaye as Chief Medical Advisor to guide the clinical and regulatory strategy for NVG-291, following positive topline results from the chronic cohort of their Phase 1b/2a spinal cord injury trial.

Dr. Divita Mathur at Case Western Reserve University received a prestigious NSF CAREER grant to develop synthetic DNA nanoparticles that can deliver therapeutic genes with precise targeting capabilities.

Trailhead Biosystems has raised $20 million in funding led by MAK Capital to enhance its portfolio of induced pluripotent stem cell (iPSC) derived cells for research applications.

The American Heart Association has funded seven research projects with $1 million to identify which patients with obesity and cardiovascular disease benefit most from GLP-1/GIP medications.

Semaglutide treatment slowed biological aging by approximately 9% and reduced epigenetic aging mortality risk by three years in HIV patients with lipohypertrophy over 32 weeks.

The FDA has granted 510(k) clearance to Bright Uro's Glean™ Urodynamics System, the first wireless, catheter-free device for monitoring bladder dysfunction in patients with lower urinary tract conditions.

University Hospitals and Case Western Reserve University launch an $8 million NIH-funded clinical trial to evaluate EsoCheck and EsoGuard technologies for detecting Barrett's Esophagus in non-GERD patients.

MedPacto partners with leading US institutions, including Stanford University and Case Western Reserve University, to conduct Phase 2 trial of vactosertib for pediatric osteosarcoma treatment.